Long-term study following people with fatty liver disease
Studies liver tissue samples from people with fatty liver disease and NASH over time.
Plain-language title generated from the registry record
Registry title: Prospective Cohort Study in Patients With NAFLD
Key facts
- Where
- Zurich, SwitzerlandSee the site
Where in Switzerland
- University Hospital Zurich, Endocrinology and DiabetologyZurich, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Zurich
- Trial code
- NCT00575133
- Record updated
- 24 February 2012
- Original description
To assess the importance of intracellular signalling pathways and its deregulation in adiposity and diabetes-related insulin resistance, liver tissue samples of patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)will be analyzed prospectively from a liver tissue bank.Read full original descriptionShow less
Multicentric, Prospective, Non-interventional, Long-term Cohort Study in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
To assess the importance of intracellular signalling pathways and its deregulation in adiposity and diabetes-related insulin resistance, liver tissue samples of patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)will be analyzed prospectively from a liver tissue bank.
Inclusion: Patients with histologically confirmed fatty liver disease.
Exclusion: Hepatotoxic medication (e.g. amiodarone); History of significant alcohol consumption; Viral hepatitis; Autoimmune hepatitis; Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency).